Compare SHAK & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | NKTR |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2014 | 1996 |
| Metric | SHAK | NKTR |
|---|---|---|
| Price | $56.92 | $64.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 7 |
| Target Price | $117.29 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,445,306,000.00 | $307,711,000.00 |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $15.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.38 | ★ 86.00 |
| 52 Week Low | $51.60 | $21.02 |
| 52 Week High | $142.20 | $109.00 |
| Indicator | SHAK | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 49.36 |
| Support Level | $52.60 | $64.30 |
| Resistance Level | $61.74 | $66.52 |
| Average True Range (ATR) | 2.55 | 3.38 |
| MACD | 0.92 | 1.26 |
| Stochastic Oscillator | 42.82 | 53.70 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.